TOKYO & SINGAPORE, March 30 (Bernama-BUSINESS WIRE) -- Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) and the Agency for Science, Technology and Research, Singapore (A*STAR) announced today that a joint research project between Chugai and A*STAR for an anti-dengue virus antibody has been selected as a grant recipient by the Global Health Innovative Technology Fund (GHIT Fund). Chugai and A*STAR have been engaged in the joint research since 2015.
This project was born through the collaboration of Chugai Pharmabody Research Pte. Ltd. (CPR), a research center of the Chugai Group in Singapore, and A*STAR’s Singapore Immunology Network (SIgN). The dengue virus that causes dengue fever is known to have four different serotypes. SIgN researchers identified a new human antibody that is highly effective in neutralizing the activity of all four dengue virus serotypes, and CPR applied Chugai’s proprietary antibody engineering technologies to optimize the antibody. This project seeks to create a new antibody drug against the dengue virus. It has been selected to receive US$5.3 million grant based on its recognition by the GHIT Fund for contributing to the “fight against neglected tropical diseases in developing countries.”
http://mrem.bernama.com/viewsm.php?idm=28791
No comments:
Post a Comment